

## Original Article

\*Share first authorship.

†Share senior authorship.

**Cite this article:** Fullana MA *et al* (2019). Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses. *Psychological Medicine* 1–16. <https://doi.org/10.1017/S0033291719001247>

Received: 8 January 2019

Revised: 2 May 2019

Accepted: 9 May 2019

### Key words:

Anxiety disorders; meta-analysis; obsessive-compulsive disorder; risk factor; umbrella review

### Author for correspondence:

Miquel A. Fullana, E-mail: [mafullana@clinic.cat](mailto:mafullana@clinic.cat)

© Cambridge University Press 2019

# Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses

Miquel A. Fullana<sup>1,2,\*</sup>, Miquel Tortella-Feliu<sup>3,\*</sup>, Lorena Fernández de la Cruz<sup>4</sup>, Jacobo Chamorro<sup>5</sup>, Ana Pérez-Vigil<sup>4</sup>, John P. A. Ioannidis<sup>6,7,8,9</sup>, Aleix Solanes<sup>10,11</sup>, Maria Guardiola<sup>10</sup>, Carmen Almodóvar<sup>10</sup>, Romina Miranda-Olivos<sup>10</sup>, Valentina Ramella-Cravaro<sup>12,13</sup>, Ana Vilar<sup>14,15</sup>, Abraham Reichenberg<sup>16,17,18,19</sup>, David Mataix-Cols<sup>4,20</sup>, Eduard Vieta<sup>21</sup>, Paolo Fusar-Poli<sup>12,22</sup>, Mar Fatjó-Vilas<sup>10,23,†</sup> and Joaquim Radua<sup>4,10,12,24,†</sup>

<sup>1</sup>Institute of Neurosciences, Hospital Clinic, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; <sup>2</sup>Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain; <sup>3</sup>University Research Institute on Health Sciences (IUNICS), University of the Balearic Islands, Mallorca, Spain; <sup>4</sup>Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden; <sup>5</sup>Anxiety Unit, Institute of Neuropsychiatry and Addictions, Parc de Salut Mar, Barcelona, Spain; <sup>6</sup>Department of Medicine, Stanford Prevention Research Center, Stanford, CA, USA; <sup>7</sup>Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA; <sup>8</sup>Meta-Research Innovation Center at Stanford, Stanford University, Stanford, CA, USA; <sup>9</sup>Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, CA, USA; <sup>10</sup>FIDMAG Germanes Hospitalaries, CIBERSAM, Barcelona, Spain; <sup>11</sup>Department of Psychiatry and Forensic Medicine, School of Medicine, Autonomous University of Barcelona, Barcelona, Spain; <sup>12</sup>Early Psychosis: Interventions and Clinical-detection Lab (EPIC), Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; <sup>13</sup>Department of Mental Health, Florence Public Health Center, Florence, Italy; <sup>14</sup>Institut de Neuropsiquiatria i Addiccions, CSMIJ Sant Martí-La Mina, Parc de Salut Mar, Barcelona, Spain; <sup>15</sup>Department of Experimental and Health Sciences, Pompeu Fabra University (UPF), Barcelona, Spain; <sup>16</sup>Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; <sup>17</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>18</sup>Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>19</sup>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>20</sup>Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden; <sup>21</sup>Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBERSAM, Barcelona, Spain; <sup>22</sup>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; <sup>23</sup>Department of Evolutionary Biology, Ecology and Environmental Sciences, Faculty of Biology, University of Barcelona, Institut de Biomedicina of the University of Barcelona (IBUB), Barcelona, Spain and <sup>24</sup>Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBERSAM, Barcelona, Spain

## Abstract

**Background.** A multitude of risk/protective factors for anxiety and obsessive-compulsive disorders have been proposed. We conducted an umbrella review to summarize the evidence of the associations between risk/protective factors and each of the following disorders: specific phobia, social anxiety disorder, generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder, and to assess the strength of this evidence whilst controlling for several biases.

**Methods.** Publication databases were searched for systematic reviews and meta-analyses examining associations between potential risk/protective factors and each of the disorders investigated. The evidence of the association between each factor and disorder was graded into convincing, highly suggestive, suggestive, weak, or non-significant according to a standardized classification based on: number of cases (>1000), random-effects *p*-values, 95% prediction intervals, confidence interval of the largest study, heterogeneity between studies, study effects, and excess of significance.

**Results.** Nineteen systematic reviews and meta-analyses were included, corresponding to 216 individual studies covering 427 potential risk/protective factors. Only one factor association (early physical trauma as a risk factor for social anxiety disorder, OR 2.59, 95% CI 2.17–3.1) met all the criteria for convincing evidence. When excluding the requirement for more than 1000 cases, five factor associations met the other criteria for convincing evidence and 22 met the remaining criteria for highly suggestive evidence.

**Conclusions.** Although the amount and quality of the evidence for most risk/protective factors for anxiety and obsessive-compulsive disorders is limited, a number of factors significantly increase the risk for these disorders, may have potential prognostic ability and inform prevention.

## Introduction

Anxiety disorders are the most common group of mental disorders and are associated with enormous societal costs (Kessler *et al.*, 2010; Craske and Stein, 2016). Both ‘genetic’ and ‘non-genetic’ (i.e. environmental) variables (as well as their interaction) have been proposed as potential risk/protective factors for anxiety disorders (Craske *et al.*, 2017), although such a distinction may be somewhat artificial, given that many risk/protective factors include both genetic and non-genetic components. The evidence on risk/protective factors for anxiety disorders has been summarized in several systematic reviews and meta-analyses. However, findings are conflicting and there have been no previous attempts to summarize in a single report the strength of the evidence for the different potential risk/protective factors for each anxiety disorder or to assess possible biases in the literature.

We present the results of an umbrella review of risk/protective factors for the most common anxiety disorders. We will focus on specific phobia, social anxiety disorder (SAD), generalized anxiety disorder (GAD), panic disorder (PD), and obsessive-compulsive disorder (OCD) – the latter having been classified as an anxiety disorder until the publication of the 5<sup>th</sup> edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association, 2013). Umbrella reviews systematically collect and assess the existing evidence from individual studies included in systematic reviews and/or meta-analyses and have an increasing role in evidence-based health care and evidence-based assessments (Ioannidis, 2009; Fusar-Poli and Radua, 2018).

In the current absence of valid biomarkers or clear mechanistic explanations for most mental disorders (Kapur *et al.*, 2012), the identification of putative (and, at least for some, modifiable) risk/protective factors may lead to the development of more efficient risk prediction models, and may offer clues for prevention and treatment (Paulus, 2015; Moreno-Peral *et al.*, 2017; Fusar-Poli *et al.*, 2018). Our aim was to systematically assess the amount of evidence and the robustness of associations between potential risk/protective factors and each of the aforementioned disorders.

## Methods

We conducted an umbrella review (Ioannidis, 2009; Fusar-Poli and Radua, 2018) to assess the relation between potential risk/protective factors and anxiety and obsessive-compulsive disorders. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher *et al.*, 2009) and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines (Stroup *et al.*, 2000) (online Supplementary Tables S1 and S2). The study protocol was pre-registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42017060090).

### Search strategy and eligibility criteria

We searched *PubMed*, *Web of Science*, and *Scopus* from inception to April 30 2018 for systematic reviews and meta-analyses of observational studies examining associations between potential risk/protective factors (see below) separately for each disorder. The search strategy used the keywords ‘systematic review’ or ‘meta-analysis’ and each of the disorders of interest. We also

hand searched the reference lists of all systematic reviews and meta-analysis reaching full-text review.

Eligibility criteria were: (1) a systematic review or meta-analysis of risk/protective factors for specific phobia, SAD, GAD, PD, or OCD as defined in any edition of the International Classification of Diseases (ICD) manual or the DSM; (2) inclusion of a healthy comparison group; and (3) studies reporting sufficient data (or that were retrievable after contacting the authors) to perform the analyses. We did not apply any language restrictions in the selection of systematic reviews or meta-analyses.

Even though we had hoped to include molecular genetic studies in the umbrella review, we found that the literature for the disorders investigated is dominated by candidate gene studies, which are known to have low credibility. Such risk factor assessment should await thus the publication of large genome-wide studies (Ioannidis *et al.*, 2008). Moreover, different analytical methods and assessment criteria are required for umbrella reviews of genetic variables (Ioannidis *et al.*, 2008).

Although in some DSM classifications previous to DSM-5 ‘panic disorder’ and ‘panic disorder with agoraphobia’ have been classified separately, we included both in our ‘panic disorder’ category. However, we have analyzed them separately where a study reported separate factors for each of these categories. We also considered separation anxiety disorder and selective mutism (‘anxiety disorders’ in the DSM-5), but they were not included due to the lack of systematic reviews and meta-analyses (online Supplementary Figs S6 and S7). Posttraumatic stress disorder (PTSD), grouped as an anxiety disorder until the publication of DSM-5, will be covered in a separate manuscript.

Further information about the search strategy and the eligibility criteria can be found in the online Supplementary material.

### Risk/protective factor definition

We used the following definition of risk factor: ‘that characteristic, variable, or hazard preceding the outcome of interest that, if present for a given individual, makes it more likely that this individual, rather than someone selected from the general population, will develop a given disorder’ (Mrazek and Haggerty, 1994; Kraemer *et al.*, 1997). Similarly, protective factors are those where risk is found to be decreased. We assessed both stable factors (e.g. sex), for which time precedence does not need to be established, and factors that are subject to change within-subject. For the latter, we required that the determination of the factor preceded the diagnosis of the outcome (i.e. the disorder) even if the information on the factor and the outcome was collected at the same time point (as in the case of cross-sectional studies). This rule ensured that there would be time precedence for the assessments of factors and outcomes, although factors may have existed even before their determination, and disorders may have also existed before their diagnosis. Furthermore, when the factor investigated was related to personality dimensions (e.g. neuroticism), we also required that personality was *assessed* before the disorder was diagnosed in order to avoid state-trait influences (Reich *et al.*, 1987). The definitions for each factor were those given in the corresponding systematic review or meta-analysis.

Following previous work (Radua *et al.*, 2018) we grouped factors into several descriptive categories: sociodemographic, psychopathology, parental psychopathology, personality dimensions, substance use, life events, perinatal complications, parental rearing styles/attachment, and others.

### Data extraction and selection

We used a systematic approach to extract and select the data. First, we identified the factors assessed in each systematic review or meta-analysis. Second, two investigators independently checked that each individual article included in the systematic review or meta-analysis met the same eligibility criteria applied to the systematic review or meta-analysis. Third, two investigators independently extracted the following data (from the systematic review or meta-analysis or, in most cases, from the individual studies): first author and year of publication; number of cases and controls; measure and size of the risk and corresponding 95% confidence intervals (CIs); specific variables depending on the measure of effect size; and whether the study was a prospective cohort. Specific variables depending on the measure of effect size were: number of cases and person-times in exposed and unexposed for incidence rate ratios (IRR), number of cases and total number of exposed and unexposed for risk ratios (RR), number of exposed and unexposed and cases and controls for odds ratios (OR), and means and standard deviations for cases and controls for standardized mean differences (SMD). Fourth, two investigators independently rated the quality of the systematic review or meta-analysis using the Assessment of Multiple Systematic Reviews (AMSTAR; Shea *et al.*, 2007) tool, with substantial interrater agreement (both weighted Cohen's kappa and intraclass correlation = 0.71; see online Supplementary material). A third investigator reviewed the extracted data to check for inconsistencies, and disagreements were resolved by consensus. For further details on the data extraction, selection, and quality assessment, see the online Supplementary material.

### Statistical analysis

We performed statistical analyses commonly used in standard meta-analyses. However, we did not use the statistics provided in the included systematic review or meta-analyses because there are differences across-studies in the methods employed and because some analyses are often not conducted (e.g. the test for an excess of significant findings).

We conducted a separate random-effects meta-analysis for each factor and disorder. The outcomes of the meta-analyses were the effect sizes with their CIs and *p*-values, and the statistics required to assess the level of evidence (see below). Depending on the factor, we used IRR, RR, OR, or SMD Hedges' *g*. For descriptive purposes, we also report OR equivalents (eOR) of IRR, RR, and Hedge's *g* (see Fusar-Poli and Radua (2018) for additional details).

We assessed between-study heterogeneity by estimating the 95% prediction interval – which evaluates the uncertainty for the effect that would be expected in a new study addressing that same association – and the  $I^2$  metric (Ioannidis *et al.*, 2007).  $I^2 > 50\%$  were considered to represent substantial heterogeneity (Higgins and Green, 2009). We also assessed whether there was evidence of small-study effects with Egger tests (Egger *et al.*, 1997), where statistical significance would mean potential reporting or publication bias in the smaller studies. Finally, excess significance (a relative excess of statistically significant findings) was assessed with a binomial test that compared the observed *v.* the expected number of studies yielding statistically significant results (Radua *et al.*, 2018).

The levels of evidence of the associations between each factor

*suggestive* (class II), *suggestive* (class III), or *weak* (class IV) (Fusar-Poli and Radua, 2018). *Convincing* evidence required a number of cases (*n*) >1000, a highly significant association ( $p < 10^{-6}$ ),  $I^2 < 50\%$ , a statistically significant 95% prediction interval, and the absence of small-study effects and excess significance bias. *Highly suggestive* evidence also required *n* > 1000, a highly significant association ( $p < 10^{-6}$ ), and that the largest study had a statistically significant effect. *Suggestive evidence* required *n* > 1000 and  $p < 10^{-3}$ . *Weak evidence* required no specific number of cases and  $p < 0.05$ . Furthermore, after collecting all the available evidence, we noticed that, with few exceptions, there were fewer than 1000 cases for most factors. Therefore, we also examined these criteria removing the requirement of *n* > 1000, so as to obtain a more fine-grained appraisal of the evidence. For associations with significant evidence (classes I–IV), we also conducted a sensitivity analysis by using only prospective cohort studies.

### Results

We included 19 systematic reviews and meta-analyses (Fig. 1 and online Supplementary Figs S1–S5). AMSTAR scores are presented in Table 1. All extracted data and results are available at: <https://www.umbrella-evidence.com/anxiety/riskfactors/>.

We extracted data for 427 factors from 216 individual studies. The number of systematic reviews and meta-analyses, individual studies assessed and included, and factors included are presented in Table 2. The groups of factors assessed in each systematic review or meta-analysis are reported in Table 1 and the specific factors in online Supplementary Table S3. Factors showing convincing, highly suggestive, or suggestive evidence of association with each disorder are presented in Table 3. All significant factors (including those showing weak evidence of association) are presented in online Supplementary Table S4.

Overall, the number of cases was greater than 1000 for 20 factors (4.68%). One-hundred eighty-three of the 427 factors (42.84%) presented a statistically significant effect ( $p < 0.05$ ) under the random-effects model, but only 91 (21.31%) had a  $p < 0.005$  and only 27 (6.32%) reached  $p < 10^{-6}$ . Twenty-five factors (36.76%) presented a large estimate of heterogeneity ( $I^2 > 50\%$ ), while for 29 factors (78.37%) the 95% prediction interval did not include the null. Additionally, evidence for small-study effects and excess significance bias was noted for 2 (5.40%) and 8 (1.87%) factors, respectively (see online Supplementary Table S4).


### Results by disorder

#### Specific phobia

No factor showed convincing or highly suggestive evidence as a risk/protective factor for specific phobia using the original umbrella review criteria. Removing the *n* > 1000 criterion, being male showed convincing evidence as protective factor. Moreover, neuroticism showed highly suggestive evidence as risk factor for the disorder, which was maintained after the sensitivity analyses (Table 3, Fig. 2, and online Supplementary Table S4).

#### Social anxiety disorder

Early physical and sexual trauma showed, respectively, convincing and suggestive evidence as risk factors for SAD. Additionally, when removing the *n* > 1000 criterion, dysthymia, insecure attachment in childhood, major depression, and neuroticism showed



**Fig. 1.** Flow chart of the literature search (see online Supplementary material for the flowcharts for each specific disorder).

**Table 1.** Systematic reviews and meta-analyses included in the umbrella review, quality scores, and groups of risk/protective factors examined, by disorder

Systematic review/ meta-analysis	AMSTAR score (0–11) <sup>a</sup>	Groups of risk/protective factors examined	Disorders examined
Brander <i>et al.</i> (2016a)	6	Socio-demographic; parental rearing styles/attachment; substance use; life events; other	OCD
Brown <i>et al.</i> (2000)	3	Life events	Specific phobia, GAD, PD
Clarner <i>et al.</i> (2015)	8	Life events	PD
Clauss and Blackford (2012)	8	Other (behavioral inhibition in childhood)	SAD
Colonnesi <i>et al.</i> (2011)	8	Parental rearing styles/attachment	SAD
Fernandes <i>et al.</i> (2015)	8	Life events	SAD, GAD, PD
Garipey <i>et al.</i> (2010)	10	Other (obesity)	GAD
Guo <i>et al.</i> (2016)	10	Socio-demographic	Specific phobia, SAD, GAD, PD, OCD
Jacobson and Newman (2017)	7	Psychopathology	Specific phobia, GAD, PD
Kedzior and Laeber (2014)	7	Substance use	Specific phobia, GAD, PD, OCD
Kisely <i>et al.</i> (2017)	11	Socio-demographic	SAD, GAD, PD
Kossowsky <i>et al.</i> (2013)	10	Psychopathology	PD
Kotov <i>et al.</i> (2010)	5	Personality dimensions	Specific phobia, SAD, GAD, OCD
Micco <i>et al.</i> (2009)	7	Parental psychopathology	SAD, GAD, PD, OCD
Moreno-Peral <i>et al.</i> (2014)	9	Socio-demographic; psychopathology; parental psychopathology; personality dimensions; substance use; life events; perinatal complications; parental rearing styles/attachment; other	GAD, PD
Moylan <i>et al.</i> (2012)	6	Substance use	Specific phobia, SAD, GAD
Osborn <i>et al.</i> (2016)	8	Other (traumatic brain injury)	GAD
Tarricone <i>et al.</i> (2012)	8	Socio-demographic	GAD
Van Steensel <i>et al.</i> (2011)	6	Psychopathology	Specific phobia

AMSTAR, Measurement tool to assess the methodological quality of systematic reviews; GAD, generalized anxiety disorder; PD, panic disorder; OCD, obsessive-compulsive disorder; SAD, social anxiety disorder.

Note: Some risk/protective factors were assessed only for some of the disorders included in the corresponding systematic review/meta-analysis.

The specific risk/protective factors assessed in each systematic review or meta-analysis are reported in online Supplementary Table S4.

<sup>a</sup>Rounded-up average of two raters.

sensitivity analyses, evidence for both trauma-related factors became weak, but the rest of factors—except insecure attachment in childhood—maintained the same level of evidence (Table 3, Fig. 2, and online Supplementary Table S4).

#### Generalized anxiety disorder

No factor showed convincing or highly suggestive evidence as a risk/protective factor for GAD. Removing the  $n > 1000$  criterion, being male showed convincing evidence as protective factor for GAD and the following factors showed highly suggestive evidence as risk factors for the disorder: psychological malaise at age 33, borderline personality disorder, parental GAD without comorbidity, early physical and sexual trauma, and behavioral inhibition (assessed as a personality dimension). After sensitivity analyses, all these factors – except both trauma-related variables – maintained the same level of evidence (Table 3, Fig. 2, and online Supplementary Table S4).

#### Panic disorder

No factor showed convincing or highly suggestive evidence as risk/protective factor for PD. Removing the  $n > 1000$  criterion, being male, separation anxiety in childhood, and early physical trauma showed convincing evidence as risk/protective factors for PD. The evidence was not maintained, however, after sensitivity analyses. Furthermore, daily cigarette smoking, panic attacks, and major depression showed highly suggestive evidence as risk factors for PD, which was maintained after sensitivity analyses (Table 3, Fig. 2, and online Supplementary Table S4).

#### Obsessive-compulsive disorder

No factor showed convincing or highly suggestive evidence as risk/protective factor for OCD. Removing the  $n > 1000$  criterion, several parental rearing style variables, neuroticism, and use of cocaine together with another drug (except marijuana) showed highly suggestive evidence as risk/protective factors for OCD.



**Table 2.** Number of systematic reviews and meta-analyses included in the umbrella review, individual studies assessed and included, and potential risk/protective factors included in the umbrella review, by disorder

Disorder	Number of systematic reviews or meta-analyses included	Number of individual studies assessed for eligibility	Number of individual studies included	Number of potential risk/protective factors included
Specific phobia	6	63	19	13
Social anxiety disorder	10	110	34	20
Generalized anxiety disorder	13	132	57	110
Panic disorder	11	144	60	78
Obsessive-compulsive disorder	6	160	46	206

However, the latter was based on a single study reporting one single case in the exposed group. Only neuroticism and use of cocaine together with another drug (except marijuana) maintained the same level of evidence after the sensitivity analyses (Table 3, Fig. 2, and online Supplementary Table S4).

## Discussion

This is, to the best of our knowledge, the first umbrella review of risk/protective factors for anxiety and obsessive-compulsive disorders. Our study provides a state-of-the-art classification of risk/protective factors based on the robustness of associations between these factors and five separate disorders, while controlling for several biases.

Using the original umbrella review criteria, early physical trauma was the single most consistent risk factor – class I – for SAD. Early sexual trauma was also associated – class III – with SAD. Several ‘traditional’ risk/protective factors for anxiety and obsessive-compulsive disorders were among those that had nominally statistically significant results (Beesdo *et al.*, 2009; Craske and Stein, 2016). Although we could not assess exactly the same factors for all disorders, a number of factors showed a similar association with several of the disorders investigated (Fig. 3). For example, being male was associated with decreased risk for specific phobia, SAD, GAD, and PD; and neuroticism was associated with increased risk for specific phobia, SAD, GAD, and OCD. Moreover, early traumatic experiences increased the risk of all disorders in which they were investigated (SAD, GAD, PD, and OCD). Although the evidence for most of these associations was rated as weak, the consistency of these signals across multiple disorders strengthens the case that they do carry prognostic potential. The fact that the same factors increased the risk for different disorders may indicate a shared liability *within* anxiety and obsessive-compulsive disorders (Blanco *et al.*, 2014). Moreover, some factors may be shared *across* mental disorders (i.e. be ‘transdiagnostic’). For example, early traumatic experiences are a significant risk factor for depressive (Köhler *et al.*, 2018), psychotic (Belbasis *et al.*, 2018; Radua *et al.*, 2018), and bipolar disorders (Bortolato *et al.*, 2017). Importantly, the results of our umbrella review provide hints not only on the presence/absence of a particular factor but also on the *loading* (weight) of that factor, which may be still unique (Uher and Zwicker, 2017).

The non-specificity of the findings for most risk factors investigated here (and probably for most risk factors for mental disorders in general) may also be partially explained by the fact that

developmental effects (including temporal dynamics and the development of comorbidity over time) are often ignored in current nosological systems. The use of longitudinal ‘staging models’ – that describe the progression from more simple or ‘pure’ disorders to more complex or comorbid disorders – has been proposed to deal with these issues. Such models could offer a better description of the developmental patterns typical to most mental disorders (Beesdo *et al.*, 2009).

Our data suggest that rather than ‘a few’ risk or protective factors with large effects, large sets of common ‘variants’ of small effects account for the risk for anxiety and obsessive-compulsive disorders. This idea, which is well established in psychiatry genetics (Anttila *et al.*, 2018; Sullivan *et al.*, 2018), seems to be also true for ‘non-purely genetic’ factors (Uher and Zwicker, 2017). Furthermore, our findings open the door to the potential development of enhanced risk prediction models (Bernardini *et al.*, 2017) and individual risk prediction scores (see Kessler *et al.*, 2014, and Shalev *et al.*, 2019 for specific examples in PTSD). In recent years, the use of polygenic risk scores has been validated in disorders such as schizophrenia (International Schizophrenia Consortium *et al.*, 2009). More recently, the use of ‘poly-environmental scores’ has been proposed (Padmanabhan *et al.*, 2017; Uher and Zwicker, 2017). Given that multiple genetic and non-genetic factors have much greater explanatory power than considering them one at a time in most mental disorders (Uher and Zwicker, 2017), it is likely that ‘poly-risk’ scores (containing both genetic and non-genetic factors) improve the prediction of mental disorders. Our data may help developing such scores for anxiety and obsessive-compulsive disorders, although the time of exposure and the cumulative nature of non-genetic risk will need to be taken into account to improve such prediction abilities (Moffitt *et al.*, 2005; Sharma *et al.*, 2016). Developmental effects – and their potential interaction with genetic variables – are difficult to study using epidemiological data, but they could be investigated using animal models (Leonardo and Hen, 2008).

The majority of factors were only classified as having weak evidence (class IV). This mainly reflects the methodological limitations of the data, where less than 5% of the factors included more than 1000 cases and where the significance of the associations for each individual factor was overall low. The (weak) strength of the associations found, together with limitations inherent to the individual study designs employed to date, precludes firm causal inferences for any of the significant factors identified in our umbrella review (Paulus, 2015). Future work to identify risk/protective factors could focus on large-scale family-based designs, that allow for a more stringent control of

**Table 3.** Risk/protective factors showing *convincing* (class I), *highly suggestive* (class II), or *suggestive* (class III) evidence of association with each disorder using the original umbrella review criteria or after removing the  $n > 1000$  cases criterion, by disorder

Disorder	Factor group	Risk/Protective factor	K	N	Measure	ES (95% CI)	p	PI sign.	I <sup>2</sup>	ET sign.	ESB sign.	LS sign.	eOR	Class	Class (-n > 1000)	Class (-n > 1000, prosp.)
Specific phobia	Socio-demographic	Male gender	9	689	OR	0.43 (0.36–0.51)	<0.000001	Yes	0%	No	No	Yes	0.43	IV	I	NA
	Personality dimensions	Neuroticism	1	79	g	0.81 (0.57–1.05)	<0.000001	NA	NA	NA	No	Yes	4.35	IV	II	II
SAD	Psychopathology	Dysthymia	1	52	IRR	14.81 (6.7–32.73)	<0.000001	NA	NA	NA	No	Yes	14.81	IV	II	II
		Major depression	1	52	IRR	9.35 (4.71–18.54)	<0.000001	NA	NA	NA	No	Yes	9.35	IV	II	II
	Personality dimensions	Neuroticism	1	89	g	0.89 (0.67–1.12)	<0.000001	NA	NA	NA	No	Yes	5.02	IV	II	II
	Life events	Early emotional trauma	3	720	OR	2.8 (1.84–4.24)	0.000001	No	36%	No	No	Yes	2.80	IV	III	III
		Early physical trauma	4	1191	OR	2.59 (2.17–3.1)	<0.000001	Yes	0	No	No	Yes	2.59	I	I	IV
		Early sexual trauma	5	1239	OR	3.18 (1.73–5.86)	0.00019	No	85%	No	No	Yes	3.18	III	III	IV
	Parental rearing styles/attachment	Insecure attachment in childhood	1	76	g	1.26 (0.91–1.61)	<0.000001	NA	NA	NA	No	Yes	9.83	IV	II	NA
	Other	Behavioral inhibition in childhood <sup>a</sup>	7	257	OR	7.52 (3.04–18.61)	0.000013	No	78%	No	Yes	Yes	7.52	IV	III	III
GAD	Socio-demographic	Age (30 to 54)	1	390	OR	2.92 (1.78–4.78)	0.000022	NA	NA	NA	No	Yes	2.92	IV	III	III
		Male gender	15	999	OR	0.5 (0.41–0.59)	<0.000001	Yes	0%	No	No	Yes	0.5	IV	I	NA
	Psychopathology	Bipolar I disorder	1	390	OR	2.58 (1.48–4.49)	0.00081	NA	NA	NA	No	Yes	2.58	IV	III	III
		Borderline personality disorder	1	390	OR	4.71 (2.93–7.57)	<0.000001	NA	NA	NA	No	Yes	4.71	IV	II	II
		History of one psychological disorder	1	288	OR	1.7 (1.27–2.26)	0.00029	NA	NA	NA	No	Yes	1.70	IV	III	III
		Internalizing disorder at age 16	1	288	OR	2.01 (1.34–3)	0.00065	NA	NA	NA	No	Yes	2.01	IV	III	III
		Internalizing disorder at age 7	1	288	OR	1.91 (1.31–2.79)	0.00081	NA	NA	NA	No	Yes	1.91	IV	III	III
		Narcissistic personality disorder	1	390	OR	2.31 (1.49–3.6)	0.00019	NA	NA	NA	No	Yes	2.31	IV	III	III

(Continued)

Table 3. (Continued.)

Disorder	Factor group	Risk/Protective factor	K	N	Measure	ES (95% CI)	p	PI sign.	I <sup>2</sup>	ET sign.	ESB sign.	LS sign.	eOR	Class	Class (-n > 1000)	Class (-n > 1000, prosp.)
		Psychological malaise at age 33	1	288	OR	4.73 (3.43–6.52)	<0.000001	NA	NA	NA	No	Yes	4.73	IV	II	II
		Schizotypal personality disorder	1	390	OR	2.6 (1.52–4.44)	0.00045	NA	NA	NA	No	Yes	2.60	IV	III	III
		Subsyndromal depression no distress	1	563	OR	2.25 (1.56–3.24)	0.000014	NA	NA	NA	No	Yes	2.25	IV	III	III
	Parental psychopathology	Anxiety	8	254	OR	3.45 (1.97–6.02)	0.000013	Yes	0%	No	No	Yes	3.45	IV	III	NA
		GAD without comorbidity	1	106	HR	3.77 (2.27–6.26)	<0.000001	NA	NA	NA	No	Yes	3.77	IV	II	II
		Major depression in both parents	1	65	OR	3.7 (2.01–6.79)	0.000024	NA	NA	NA	No	Yes	3.70	IV	III	III
		Major depression in one parent	1	79	OR	2.51 (1.47–4.29)	0.00074	NA	NA	NA	No	Yes	2.51	IV	III	III
	Personality dimensions	Behavioral inhibition <sup>a</sup>	1	106	HR	1.97 (1.66–2.33)	<0.000001	NA	NA	NA	No	Yes	1.97	IV	II	II
		Harm avoidance	1	106	HR	1.69 (1.37–2.09)	0.000001	NA	NA	NA	No	Yes	1.69	IV	III	III
	Substance use	Cannabis use	1	83	OR	2.79 (1.55–5.02)	0.00059	NA	NA	NA	No	Yes	2.79	IV	III	III
	Life events	Early physical trauma	1	350	OR	2.39 (1.92–2.98)	<0.000001	NA	NA	NA	No	Yes	2.39	IV	II	NA
		Early sexual trauma	1	350	OR	3.28 (2.6–4.14)	<0.000001	NA	NA	NA	No	Yes	3.28	IV	II	NA
		Physical abuse in childhood	1	165	OR	1.82 (1.33–2.48)	0.00017	NA	NA	NA	No	Yes	1.82	IV	III	IV
		Separation events in childhood	1	106	HR	2.44 (1.54–3.85)	0.00013	NA	NA	NA	No	Yes	2.44	IV	III	IV
	Other	Received mental health treatment from 20 to 32	1	52	OR	6.15 (2.81–13.45)	0.000005	NA	NA	NA	No	Yes	6.15	IV	III	III
		Received psychiatric medication from 20 to 32	1	52	OR	5.19 (1.98–13.55)	0.00078	NA	NA	NA	No	Yes	5.19	IV	III	III
PD	Socio-demographic	Male gender	11	439	OR	0.5 (0.39–0.64)	<0.000001	Yes	0%	No	No	Yes	0.5	IV	I	NA
	Psychopathology	Major depression	2	771	OR	2.03 (1.66–2.49)	<0.000001	NA	0%	NA	No	Yes	2.03	IV	II	II
		Panic attacks	1	811	OR	2.73 (1.93–3.88)	<0.000001	NA	NA	NA	No	Yes	2.73	IV	II	II



	Post-traumatic stress disorder	1	224	OR	2.59 (1.5–4.47)	0.00062	NA	NA	NA	No	yYes	2.59	IV	III	III	
	Separation anxiety in childhood	10	880	OR	6.11 (4.31–8.66)	<0.000001	Yes	5%	No	No	Yes	6.11	IV	I	NA	
Parental psychopathology	Panic attacks (for PDA)	1	54	OR	3.93 (1.91–8.07)	0.00019	NA	NA	NA	No	Yes	3.93	IV	III	III	
Substance use	Cigarette smoking (daily)	2	201	HR	3.46 (2.21–5.41)	<0.000001	NA	21%	NA	No	Yes	3.46	IV	II	II	
	Cigarette smoking (persistence in daily smokers)	1	51	HR	14.46 (4.81–43.5)	0.000002	NA	NA	NA	No	Yes	14.46	IV	III	III	
	Cigarette smoking (persistence in prior daily smokers)	1	149	HR	3.18 (1.99–5.1)	0.000001	NA	NA	NA	No	Yes	3.18	IV	III	III	
Life events	Early emotional trauma	1	123	OR	2.71 (1.57–4.68)	0.00035	NA	NA	NA	No	Yes	2.71	IV	III	NA	
	Early trauma	2	194	OR	3.56 (1.86–6.8)	0.00012	NA	0	NA	No	Yes	3.56	IV	III	NA	
	Early physical trauma	4	449	OR	2.46 (1.95–3.11)	<0.000001	Yes	0%	No	No	Yes	2.46	IV	I	III	
	Early sexual trauma	5	518	OR	2.91 (1.67–5.08)	0.00017	No	73%	No	No	Yes	2.91	IV	III	III	
Other	Joint hypermobility syndrome	1	14	RR	22.34 (5.3–94.29)	0.000023	NA	NA	NA	No	Yes	22.34	IV	III	III	
OCD	Socio-demographic	Paternal age >35	1	122	OR	5.34 (2.15–13.27)	0.00030	NA	NA	NA	No	Yes	5.34	IV	III	NA
	Perinatal complications	Ear infection	1	68	OR	57.81 (7.59–440.61)	0.00009	NA	NA	NA	No	Yes	57.81	IV	III	NA
		Early developmental problems	1	13	OR	11.53 (2.84–46.78)	0.00062	NA	NA	NA	No	Yes	11.53	IV	III	NA
		Excess weight gain in pregnancy	1	68	OR	9.31 (2.62–33.1)	0.00057	NA	NA	NA	No	Yes	9.31	IV	III	NA
		Hyperemesis	1	68	OR	8 (3.21–19.97)	0.000008	NA	NA	NA	No	Yes	8.00	IV	III	NA
		Medication during pregnancy	1	68	OR	5.45 (2.6–11.45)	0.000007	NA	NA	NA	No	Yes	5.45	IV	III	NA
		Mumps	1	68	OR	11.41 (3.23–40.28)	0.00015	NA	NA	NA	No	Yes	11.41	IV	III	NA
		Other postnatal problems	1	68	OR	5.81 (2.04–16.52)	0.00096	NA	NA	NA	No	Yes	5.81	IV	III	NA
		Other problems in pregnancy	1	68	OR	12.18 (3.46–42.9)	0.0001	NA	NA	NA	No	Yes	12.18	IV	III	NA
		Throat infection	1	68	OR	4.7 (2.28–9.7)	0.000028	NA	NA	NA	No	Yes	4.70	IV	III	NA


(Continued)

Table 3. (Continued.)


Disorder	Factor group	Risk/Protective factor	K	N	Measure	ES (95% CI)	p	PI sign.	I <sup>2</sup>	ET sign.	ESB sign.	LS sign.	eOR	Class	Class (-n > 1000)	Class (-n > 1000, prosp.)
	Substance use	Alcohol use disorder	1	105	RR	2.41 (1.6–3.62)	0.000024	NA	NA	NA	No	Yes	2.41	IV	III	III
		Use of cocaine and others (no marijuana)	1	105	RR	5.92 (4.97–7.05)	<0.000001	NA	NA	NA	No	Yes	5.92	IV	II	II
	Life events	Emotional neglect in childhood	1	74	g	0.75 (0.32–1.18)	0.00066	NA	NA	NA	No	Yes	3.90	IV	III	NA
		History of verbal abuse in family	1	33	OR	4.36 (1.88–10.11)	0.00061	NA	NA	NA	No	Yes	4.36	IV	III	NA
		Sexual assault in childhood	2	32	RR	4.03 (1.83–8.87)	0.00052	NA	0	NA	No	Yes	4.03	IV	III	NA
	Personality dimensions	Neuroticism	1	62	g	1.23 (0.96–1.5)	<0.000001	NA	NA	NA	No	Yes	9.31	IV	II	II
	Parental rearing styles/attachment	Interference from father	1	94	g	0.85 (0.55–1.14)	<0.000001	NA	NA	NA	No	Yes	4.67	IV	II	NA
		Overprotection from father	6	716	g	0.44 (0.21–0.68)	0.00017	No	65%	No	No	Yes	2.24	III	III	NA
		Punishment from father	1	94	g	0.71 (0.42–1)	0.000001	NA	NA	NA	No	Yes	3.62	IV	III	NA
		Refusal from father	1	94	g	1.28 (0.98–1.59)	<0.000001	NA	NA	NA	No	Yes	10.19	IV	II	NA
		Warmth from father	3	248	g	-0.64 (-0.87 to -0.42)	<0.000001	No	23%	No	No	Yes	0.31	IV	II	NA
	Other	Postpartum	1	29	OR	12.05 (3.5–41.52)	0.000081	NA	NA	NA	No	Yes	12.05	IV	III	NA

Class, class of evidence, Class (-n > 1000)- class of evidence after removing the n > 1000 cases criterion, Class (-n > 1000, prosp.)- class of evidence after removing the n > 1000 cases criterion and after sensitivity analyses (including only prospective studies); CI, confidence interval; ES, effect size; ET, Egger test; eOR, equivalent odds ratio; ESB, excess significance bias; g, Hedge's g; GAD, generalized anxiety disorder; HR, hazard ratio; I<sup>2</sup>, heterogeneity; IRR, incidence rate ratio; K, number of studies for each factor; LS, largest study with significant effect; N, number of cases; NA, not assessable; ns, not significant; OCD, obsessive-compulsive disorder; OR, odds ratio; PD, panic disorder; PDA, panic disorder with agoraphobia; PI, prediction interval; SAD, social anxiety disorder; sign., significant; RR, relative risk.

<sup>a</sup>'Behavioral inhibition' referred to 'the chronic tendency to respond to novel persons, places, and objects with wariness or avoidant behaviours' in one meta-analysis (Clauss and Blackford, 2012) and to a personality/character dimension referring to 'consistent restraint in response to social and non social situations' in one systematic review (Moreno-Peral et al., 2014).



**Fig. 2.** Forest plots of risk (in red) and protective (in green) factors showing *convincing* (class I) or *highly suggestive* (class II) evidence of association with each disorder, after removing the  $n > 1000$  cases criterion.



**Fig. 3.** Forest plots of risk/protective factors assessed in at least four of the disorders under study and showing convincing (class I) or highly suggestive (class II) evidence of association with at least one of the disorders, after removing the  $n > 1000$  cases criterion.

unmeasured familial confounders (D'Onofrio *et al.*, 2013) and should improve the confidence in the identification of 'non-purely genetic' risk/protective factors that are in the causal pathway for anxiety and obsessive-compulsive disorders. For example, recent population-based work in OCD has confirmed that a range of perinatal complications are robustly associated with the disorder, even after strict control of unmeasured genetic and environmental confounders, and that the number of perinatal complications cumulatively contribute to risk for the disorder (Brander *et al.*, 2016b). Similarly, as the field of psychiatric genetics is clearly shifting away from the candidate gene approach into the less arbitrary genome-wide association studies (GWAS) approach, the identification of genetic variants implicated in these disorders should increase dramatically in the next few years, as exemplified by the recent formation of an anxiety disorders group within the psychiatric genetics consortium (Sullivan *et al.*, 2018).


We also note that we identified very few protective factors that were not reciprocal to risk factors. This indicates that most research so far has focused on adverse/negative factors, and highlights another important aspect that will need to be addressed in future studies.

Our results may also offer opportunities for prevention. Current prevention programs for anxiety disorders have shown modest benefits (Moreno-Peral *et al.*, 2017) and there is a need for new strategies. Our findings lend support to identifying those individuals with several risk factors for inclusion in prevention programs (Blanco *et al.*, 2014). Large sets of risk factors of small effects seem to account for the risk for anxiety and obsessive-compulsive disorders, and therefore interventions that try to modulate several of them concurrently should be devised. For example, parental psychopathology and parental rearing styles were significant risk factors for several of the disorders investigated here and could be a combined target for prevention efforts. Recent data on moderators and mediators of prevention strategies should help optimise such efforts (Ginsburg *et al.*, 2015). Our results also support focusing on those modifiable risk factors with the largest effects (e.g. trauma), and whose reduction would have a greater prospective impact (Li *et al.*, 2016). Claims of success should await the results of randomized trials, since observational associations may not necessarily represent causal effects.

Our study has several strengths. We used systematic search methods and both the study selection and data extraction were conducted by independent raters. Moreover, we assessed that each individual study included in the systematic review or meta-analysis fulfilled our inclusion criteria and used standard approaches to assess the methodological quality of the systematic reviews or meta-analysis (Fusar-Poli and Radua, 2018). We offer as online Supplementary material all data collected in our umbrella review. Beyond encouraging open science, this databank may contribute to the creation of a database of risk/protective factors for anxiety and obsessive-compulsive disorders that can be updated in the future. We also note several limitations. First, we assessed each of disorders separately and did not use a mixed 'anxiety disorders' category as an outcome. There have been changes in the specific disorders included under the 'anxiety disorders' category, complicating the interpretation of such analyses. Second, we collected only information about factors assessed in systematic reviews and meta-analyses, and studies not included in this type of publication were not eligible for inclusion. Moreover, not all factors were evaluated for all the disorders. Third, we did not assess the quality of the individual studies

included in the systematic reviews and meta-analyses (because this is beyond the scope of an umbrella review). Moreover, there may be differences across-studies in the exact definitions and methods of assessment for each factor. Finally, the almost ubiquitously limited amount of evidence made us explore also what would happen if we removed the need for >1000 cases to have highly suggestive evidence. Nevertheless, great caution is needed in trusting associations, no matter how strong and consistent, where data are sparse.

In summary, we found a number of nominally statistically significant risk and protective factors for anxiety and obsessive-compulsive disorders, although very few were supported by robust evidence. The limited amount of evidence was the main restricting factor, and this means that there is plenty of room to improve the standards of evidence in this field. Our findings may help optimize current prediction models and may provide hints for testing prevention strategies.

**Author ORCIDs.**  Miquel A. Fullana, 0000-0003-3863-5223.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291719001247>.

**Acknowledgements.** Dr Fernández de la Cruz is supported by a Junior Researcher grant from the Swedish Research Council for Health, Working Life and Welfare (FORTE grant number 2015-00569). Ms. Pérez-Vigil is supported by a grant from the Alicia Koplowitz Foundation. Drs. Vieta, Radua, and Fatjó-Vilas have received support from the Instituto de Salud Carlos III, Ministry of Economy and Competitiveness of Spain (PI 12/00912; CP14/00041; CD16/00264), integrated into the Plan Nacional de I+D+I and cofounded by ISCIII- Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER) and Centro para la Investigación Biomédica en Red de Salud Mental (CIBERSAM). Dr Vieta has also received support from Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2014\_SGR\_398), Seventh European Framework Programme (ENBREC), and the Stanley Medical Research Institute. Dr Fatjó-Vilas has also received support from Comissionat per a Universitats i Recerca del DIUE, of the Generalitat de Catalunya regional authorities (2017\_SGR\_1271).

**Conflict of interest.** Dr Fernández de la Cruz and Prof. Mataix-Cols receive royalties for contributing articles to UpToDate, Wolters Kluwer Health. Dr Vieta has received grants and honoraria from AB-Biotics, Allergan, Angelini, AstraZeneca, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen, Lundbeck, Medscape, Otsuka, Pfizer, Sanofi-Aventis, Sunovion, and Takeda as well as from the CIBERSAM, Grups Consolidats de Recerca 2014 (SGR 398), the Seventh European Framework Programme (ENBREC), Horizon 2020 (R-LINK) and the Stanley Medical Research Institute. The rest of authors report no competing interests.

**Ethical standards.** The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

## References

- American Psychiatric Association (2013). *Diagnostic and Statistical Manual of Mental Disorders*, 5th Edn. Washington, DC: American Psychiatric Association.
- Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, Letenneur L, Hannequin D, Amouyel P, Boland A, Deleuze J-F, Duron E, Vardarajan BN, Reitz C, Goate AM, Huentelman MJ, Kamboh MI, Larson EB, Rogaeva E, St George-Hyslop P, Hakonarson H, Kukull WA, Farrer LA, Barnes LL,

- Beach TG, Demirci FY, Head E, Hulette CM, Jicha GA, Kauwe JSK, Kaye JA, Leverenz JB, Levey AI, Lieberman AP, Pankratz VS, Poon WW, Quinn JF, Saykin AJ, Schneider LS, Smith AG, Sonnen JA, Stern RA, Van Deerlin VM, Van Eldik LJ, Harold D, Russo G, Rubinsztein DC, Bayer A, Tsolaki M, Proitsi P, Fox NC, Hampel H, Owen MJ, Mead S, Passmore P, Morgan K, Nöthen MM, Schott JM, Rossor M, Lupton MK, Hoffmann P, Kornhuber J, Lawlor B, McQuillin A, Al-Chalabi A, Bis JC, Ruiz A, Boada M, Seshadri S, Beiser A, Rice K, van der Lee SJ, De Jager PL, Geschwind DH, Riemenschneider M, Riedel-Heller S, Rotter JJ, Ransmayr G, Hyman BT, Cruchaga C, Alegret M, Winsvold B, Palta P, Farh K-H, Cuenca-Leon E, Furlotte N, Kurth T, Ligthart L, Terwindt GM, Freilinger T, Ran C, Gordon SD, Borck G, Adams HHH, Lehtimäki T, Wedenoja J, Buring JE, Schürks M, Hrafnsdottir M, Hottenga J-J, Penninx B, Artto V, Kaunisto M, Vepsäläinen S, Martin NG, Montgomery GW, Kurki MI, Hämäläinen E, Huang H, Huang J, Sandor C, Webber C, Muller-Myhsok B, Schreiber S, Salomaa V, Leohrer E, Göbel H, Macaya A, Pozo-Rosich P, Hansen T, Werge T, Kaprio J, Metspalu A, Kubisch C, Ferrari MD, Belin AC, van den Maagdenberg AMJM, Zwart J-A, Boomsma D, Eriksson N, Olesen J, Chasman DI, Nyholt DR, Anney R, Avbersek A, Baum L, Berkovic S, Bradfield J, Buono R, Catarino CB, Cossette P, De Jonghe P, Depondt C, Dlugos D, Ferraro TN, French J, Hjalgrim H, Jamnadas-Khoda J, Kälviäinen R, Kunz WS, Lerche H, Leu C, Lindhout D, Lo W, Lowenstein D, McCormack M, Møller RS, Molloy A, Ng P-W, Oliver K, Privitera M, Radtke R, Ruppert A-K, Sander T, Schachter S, Schankin C, Scheffer I, Schoch S, Sisodiya SM, Smith P, Sperling M, Striano P, Surges R, Thomas GN, Visscher F, Whelan CD, Zara F, Heinzen EL, Marson A, Becker F, Stroink H, Zimprich F, Gasser T, Gibbs R, Heutink P, Martínez M, Morris HR, Sharma M, Ryten M, Mok KY, Pulit S, Bevan S, Holliday E, Attia J, Batty T, Boncoraglio G, Thijs V, Chen W-M, Mitchell B, Rothwell P, Sharma P, Sudlow C, Vicente A, Markus H, Kourkoulis C, Pera J, Raffeld M, Silliman S, Boraska Perica V, Thornton LM, Huckins LM, William Rayner N, Lewis CM, Gratacos M, Rybakowski F, Keski-Rahkonen A, Raevuori A, Hudson JI, Reichborn-Kjennerud T, Monteleone P, Karwautz A, Mannik K, Baker JH, O'Toole JK, Trace SE, Davis OSP, Helder SG, Ehrlich S, Herpertz-Dahlmann B, Danner UN, van Elburg AA, Clementi M, Forzan M, Docampo E, Lissowska J, Hauser J, Tortorella A, Maj M, Gonidakis F, Tziouvas K, Papezova H, Yilmaz Z, Wagner G, Cohen-Woods S, Herms S, Julià A, Rabionet R, Dick DM, Ripatti S, Andreassen OA, Espeseth T, Lundervold AJ, Steen VM, Pinto D, Scherer SW, Aschauer H, Schosser A, Alfredsson L, Padyukov L, Halmi KA, Mitchell J, Strober M, Bergen AW, Kaye W, Szatkiewicz JP, Cormand B, Ramos-Quiroga JA, Sánchez-Mora C, Ribasés M, Casas M, Hervas A, Arranz MJ, Haavik J, Zayats T, Johansson S, Williams N, Elia J, Dempfle A, Rothenberger A, Kuntsi J, Oades RD, Banaschewski T, Franke B, Buitelaar JK, Arias Vasquez A, Doyle AE, Reif A, Lesch K-P, Freitag C, Rivero O, Palmason H, Romanos M, Langley K, Rietschel M, Witt SH, Dalsgaard S, Børglum AD, Waldman I, Wilmot B, Molly N, Bau CHD, Crosbie J, Schachar R, Loo SK, McGough JJ, Grevet EH, Medland SE, Robinson E, Weiss LA, Bacchelli E, Bailey A, Bal V, Battaglia A, Betancur C, Bolton P, Cantor R, Celestino-Soper P, Dawson G, De Rubeis S, Duque F, Green A, Klauck SM, Leboyer M, Levitt P, Maestrini E, Mane S, De-Luca DM, Parr J, Regan R, Reichenberg A, Sandin S, Vorstman J, Wassink T, Wijsman E, Cook E, Santangelo S, Delorme R, Rogé B, Magalhaes T, Arking D, Schulze TG, Thompson RC, Strohmaier J, Matthews K, Melle I, Morris D, Blackwood D, McIntosh A, Bergen SE, Schalling M, Jamain S, Maaser A, Fischer SB, Reinbold CS, Fullerton JM, Grigoriou-Serbanescu M, Guzman-Parra J, Mayoral F, Schofield PR, Cichon S, Mühleisen TW, Degenhardt F, Schumacher J, Bauer M, Mitchell PB, Gershon ES, Rice J, Potash JB, Zandi PP, Craddock N, Ferrier IN, Alda M, Rouleau GA, Turecki G, Ophoff R, Pato C, Anjorin A, Stahl E, Leber M, Czerni PM, Edenberg HJ, Cruceanu C, Jones IR, Posthuma D, Andlauer TFM, Forstner AJ, Streit F, Baune BT, Air T, Sinnamón G, Wray NR, MacIntyre DJ, Porteous D, Homuth G, Rivera M, Grove J, Middeldorp CM, Hickie I, Pergadia M, Mehta D, Smit JH, Jansen R, de Geus E, Dunn E, Li QS, Nauck M, Schoevers RA, Beekman ATF, Knowles JA, Viktorin A, Arnold P, Barr CL, Bedoya-Berrio G, Joseph Bienvenu O, Brentani H, Burton C, Camarena B, Cappi C, Cath D, Cavallini M, Cusi D, Darrow S, Denys D, Derks EM, Dietrich A, Fernandez T, Figeo M, Freimer N, Gerber G, Grados M, Greenberg E, Hanna GL, Hartmann A, Hirschtritt ME, Hoekstra PJ, Huang A, Huyser C, Illmann C, Jenike M, Kuperman S, Leventhal B, Lochner C, Lyon GJ, Macciardi F, Madruga-Garrido M, Malaty IA, Maras A, McGrath L, Miguel EC, Mir P, Nestadt G, Nicolini H, Okun MS, Pakstis A, Paschou P, Piacentini J, Pittenger C, Plessen K, Ramensky V, Ramos EM, Reus V, Richter MA, Riddle MA, Robertson MM, Roessner V, Rosário M, Samuels JF, Sandor P, Stein DJ, Tsetsof F, Van Nieuwerburgh F, Weatherall S, Wendland JR, Wolanczyk T, Worbe Y, Zai G, Goes FS, McLaughlin N, Nestadt PS, Grabe H-J, Depienne C, Konkashbaev A, Lanzagorta N, Valencia-Duarte A, Bramon E, Buccola N, Cahn W, Cairns M, Chong SA, Cohen D, Crespo-Facorro B, Crowley J, Davidson M, DeLisi L, Dinan T, Donohoe G, Drapeau E, Duan J, Haan L, Hougaard D, Karachanak-Yankova S, Khrunin A, Klovinis J, Kučinskas V, Chee Keong JL, Limborska S, Loughland C, Lönnqvist J, Maher B, Mattheisen M, McDonald C, Murphy KC, Murray R, Nenadic I, van Os J, Pantelis C, Pato M, Petryshen T, Quedest D, Roussos P, Sanders AR, Schall U, Schwab SG, Sim K, So H-C, Stögmann E, Subramaniam M, Toncheva D, Waddington J, Walters J, Weiser M, Cheng W, Cloninger R, Curtis D, Gejman PV, Henskens F, Mattingdal M, Oh S-Y, Scott R, Webb B, Breen G, Churchhouse C, Bulik CM, Daly M, Dichgans M, Faraone SV, Guerreiro R, Holmans P, Kendler KS, Koeleman B, Mathews CA, Price A, Scharf J, Sklar P, Williams J, Wood NW, Cotsapas C, Palotie A, Smoller JW, Sullivan P, Rosand J, Corvin A and Neale BM (2018) Analysis of shared heritability in common disorders of the brain. *Science* 360, eaap8757.
- Beesdo K, Knappe S and Pine DS (2009) Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. *Psychiatric Clinics of North America* 32, 483–524.
- Belbas L, Köhler CA, Stefanis N, Stubbs B, van Os J, Vieta E, Seeman MV, Arango C, Carvalho AF and Evangelou E (2018) Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. *Acta Psychiatrica Scandinavica* 137, 88–97.
- Bernardini F, Attademo L, Cleary SD, Luther C, Shim RS, Quartesan R and Compton MT (2017) Risk prediction models in psychiatry. *The Journal of Clinical Psychiatry* 78, 572–583.
- Blanco C, Rubio J, Wall M, Wang S, Jiu CJ and Kendler KS (2014) Risk factors for anxiety disorders: common and specific effects in a national sample. *Depression and Anxiety* 31, 756–764.
- Bortolato B, Köhler CA, Evangelou E, León-Caballero J, Solmi M, Stubbs B, Belbas L, Pacchiarotti I, Kessing LV, Berk M, Vieta E and Carvalho AF (2017) Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. *Bipolar Disorders* 19, 84–96.
- Brander G, Pérez-Vigil A, Larsson H and Mataix-Cols D (2016a) Systematic review of environmental risk factors for obsessive-compulsive disorder: a proposed roadmap from association to causation. *Neuroscience & Biobehavioral Reviews* 65, 36–62.
- Brander G, Rydell M, Kuja-Halkola R, Fernández de la Cruz LF, Lichtenstein P, Serlachius E, Rik C, Almqvist C, D'Onofrio BM, Larsson H and Mataix-Cols D (2016b) Association of perinatal risk factors with obsessive-compulsive disorder: a population-based birth cohort, sibling control study. *JAMA Psychiatry* 73, 1135–1144.
- Brown ES, Fulton MK, Wilkeson A and Petty F (2000) The psychiatric sequelae of civilian trauma. *Comprehensive Psychiatry* 41, 19–23.
- Clarner A, Graessel E, Scholz J, Niedermeier A, Uter W and Drexler H (2015) Work-related posttraumatic stress disorder (PTSD) and other emotional diseases as consequence of traumatic events in public transportation: a systematic review. *International Archives of Occupational and Environmental Health* 88, 549–564.



- Clauss JA and Blackford JU (2012) Behavioral inhibition and risk for developing social anxiety disorder: a meta-analytic study. *Journal of the American Academy of Child and Adolescent Psychiatry* **51**, 1066–1075.
- Colonnese C, Draijer EM, Stams GJJM, van der Bruggen CO, Bögels SM and Noom MJ (2011) The relation between insecure attachment and child anxiety: a meta-analytic review. *Journal of Clinical Child and Adolescent Psychology* **40**, 630–645.
- Craske MG and Stein MB (2016) Anxiety. *The Lancet* **388**, 3048–3059.
- Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM and Wittchen H-U (2017) Anxiety disorders. *Nature Reviews Disease Primers* **3**, 17024.
- D’Onofrio BM, Lahey BB, Turkheimer E and Lichtenstein P (2013) Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. *American Journal of Public Health* **103**, S46–S55.
- Egger M, Davey Smith G, Schneider M and Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *British Medical Journal* **315**, 629–634.
- Fernandes V, Osório FL, Osório F, Preto R and Paulo S (2015) Are there associations between early emotional trauma and anxiety disorders? Evidence from a systematic literature review and meta-analysis. *European Psychiatry* **30**, 756–764.
- Fusar-Poli P, Hijazi Z, Stahl D and Steyerberg EW (2018) The science of prognosis in psychiatry. *JAMA Psychiatry* **75**, 1289–1297.
- Fusar-Poli P and Radua J (2018) Ten simple rules for conducting umbrella reviews. *Evidence Based Mental Health* **21**, 95–100.
- Garipey G, Nitka D and Schmitz N (2010) The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. *International Journal of Obesity (2005)* **34**, 407–419.
- Ginsburg GS, Drake KL, Tein J-Y, Teetsel R and Riddle MA (2015) Preventing onset of anxiety disorders in offspring of anxious parents: a randomized controlled trial of a family-based intervention HHS public access. *American Journal of Psychiatry* **172**, 1207–1214.
- Guo X, Meng Z, Huang G, Fan J, Zhou W, Ling W, Jiang J, Long J and Su L (2016) Meta-analysis of the prevalence of anxiety disorders in mainland China from 2000 to 2015. *Scientific Reports* **6**, 28033.
- Higgins JPT and Green S (2009). *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0.
- International Schizophrenia Consortium IS, Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF and Sklar P (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748–752.
- Ioannidis JPA (2009) Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. *Canadian Medical Association Journal* **181**, 488–493.
- Ioannidis JPA, Patsopoulos NA and Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. *BMJ* **335**, 914–916.
- Ioannidis JPA, Boffetta P, Little J, O’Brien TR, Uitterlinden AG, Vineis P, Balding DJ, Chokkalingam A, Dolan SM, Flanders WD, Higgins JPT, McCarthy MI, McDermott DH, Page GP, Rebbeck TR, Seminara D and Khoury MJ (2008) Assessment of cumulative evidence on genetic associations: interim guidelines. *International Journal of Epidemiology* **37**, 120–132.
- Jacobson NC and Newman MG (2017) Anxiety and depression as bidirectional risk factors for one another: a meta-analysis of longitudinal studies. *Psychological Bulletin* **143**, 1155–1200.
- Kapur S, Phillips AG and Insel TR (2012) Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? *Molecular Psychiatry* **17**, 1174–1179.
- Kedzior KK and Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population—a meta-analysis of 31 studies. *BMC Psychiatry* **14**, 136.
- Kessler RC, Ruscio AM, Shear K and Wittchen H-U (2010) Epidemiology of anxiety disorders. *Current Topics in Behavioral Neurosciences* **2**, 21–35.
- Kessler RC, Rose S, Koenen KC, Karam EG, Stang PE, Stein DJ, Heeringa SG, Hill ED, Liberzon I, McLaughlin KA, McLean SA, Pennell BE, Petukhova M, Rosellini AJ, Ruscio AM, Shahly V, Shalev AY, Silove D, Zaslavsky AM, Angermeyer MC, Bromet EJ, De Almeida JMC, De Girolamo G, De Jonge P, Demyttenaere K, Florescu SE, Gureje O, Haro JM, Hinkov H, Kawakami N, Kovess-Masfety V, Lee S, Medina-Mora ME, Murphy SD, Navarro-Mateu F, Piazza M, Posada-Villa J, Scott K, Torres Y and Viana MC (2014) How well can post-traumatic stress disorder be predicted from pre-trauma risk factors? An exploratory study in the WHO World Mental Health Surveys. *World Psychiatry* **13**, 265–274.
- Kisely S, Alichniewicz KK, Black EB, Siskind D, Spurling G and Toombs M (2017) The prevalence of depression and anxiety disorders in indigenous people of the Americas: a systematic review and meta-analysis. *Journal of Psychiatric Research* **84**, 137–152.
- Köhler CA, Evangelou E, Stubbs B, Solmi M, Veronese N, Belbasis L, Bortolato B, Melo MCA, Coelho CA, Fernandes BS, Olfson M, Ioannidis JPA and Carvalho AF (2018) Mapping risk factors for depression across the lifespan: an umbrella review of evidence from meta-analyses and Mendelian randomization studies. *Journal of Psychiatric Research* **103**, 189–207.
- Kossowsky J, Pfaltz MC, Schneider S, Taeymans J, Locher C and Gaab J (2013) The separation anxiety hypothesis of panic disorder revisited: a meta-analysis. *American Journal of Psychiatry* **170**, 768–781.
- Kotov R, Gamez W, Schmidt F and Watson D (2010) Linking ‘Big’ personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. *Psychological Bulletin* **136**, 768–821.
- Kraemer HC, Kazdin AE, Offord DR, Kessler RC, Jensen PS and Kupfer DJ (1997) *Coming to terms with the terms of risk*. *Archives of General Psychiatry* **54**, 337–343.
- Leonardo ED and Hen R (2008) Anxiety as a developmental disorder. *Neuropsychopharmacology* **33**, 134–140.
- Li M, D’Arcy C and Meng X (2016) Maltreatment in childhood substantially increases the risk of adult depression and anxiety in prospective cohort studies: systematic review, meta-analysis, and proportional attributable fractions. *Psychological Medicine* **46**, 717–730.
- Micco JA, Henin A, Mick E, Kim S, Hopkins CA, Biederman J and Hirshfeld-Becker DR (2009) Anxiety and depressive disorders in offspring at high risk for anxiety: a meta-analysis. *Journal of Anxiety Disorders* **23**, 1158–1164.
- Moffitt TE, Caspi A and Rutter M (2005) Strategy for investigating interactions between measured genes and measured environments. *Archives of General Psychiatry* **62**, 473–481.
- Moher D, Liberati A, Tetzlaff J and Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* **339**, b2535–b2535.
- Moreno-Peral P, Conejo-Cerón S, Motrico E, Rodríguez-Morejón A, Fernández A, García-Campayo J, Roca M, Serrano-Blanco A, Rubio-Valera M and Bellón JÁ (2014) Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies. *Journal of Affective Disorders* **168**, 337–348.
- Moreno-Peral P, Conejo-Cerón S, Rubio-Valera M, Fernández A, Navas-Campaña D, Rodríguez-Morejón A, Motrico E, Rigabert A, De Dios Luna J, Martín-Pérez C, Rodríguez-Bayón A, Ballesta-Rodríguez MI, Luciano JV and Bellón JÁ (2017) Effectiveness of psychological and/or educational interventions in the prevention of anxiety: a systematic review, meta-analysis, and meta-regression. *JAMA Psychiatry* **74**, 1021–1029.
- Moylan S, Jacka FN, Pasco JA and Berk M (2012) Cigarette smoking, nicotine dependence and anxiety disorders: a systematic review of population-based, epidemiological studies. *BMC Medicine* **10**, 123.
- Mrazek PJ and Haggerty RJ (1994) *Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research*. vol. 636. Washington, DC: National Academies Press.
- Osborn A, Mathias J and Fairweather-Schmidt A (2016) Prevalence of anxiety following adult traumatic brain injury: a meta-analysis comparing measures, samples and postinjury intervals. *Neuropsychology* **30**, 247–261.
- Padmanabhan JL, Shah JL, Tandon N and Keshavan MS (2017) The “poly-environmental risk score”: aggregating environmental risk factors predicts conversion to psychosis in familial high-risk subjects. *Schizophrenia Research* **181**, 17–22.
- Paulus MP (2015) Pragmatism instead of mechanism: a call for impactful biological psychiatry. *JAMA Psychiatry* **72**, 631–632.
- Radua J, Ramella-Cravaro V, Ioannidis JPA, Reichenberg A, Phipphothasane N, Amir T, Yenn Thoo H, Oliver D, Davies C,

- Morgan C, McGuire P, Murray RM and Fusar-Poli P (2018) What causes psychosis? An umbrella review of risk and protective factors. *World Psychiatry* **17**, 49–66.
- Reich J, Noyes R, Hirschfeld R, Coryell W and O’Gorman T (1987) State and personality in depressed and panic patients. *American Journal of Psychiatry* **144**, 181–187.
- Shalev AY, Gevonden M, Ratanatharathorn A, Laska E, van der Mei WF, Qi W, Lowe S, Lai BS, Bryant RA, Delahanty D, Matsuoka YJ, Olf M, Schnyder U, Seedat S, DeRoon-Cassini TA, Kessler RC and Koenen KC (2019) Estimating the risk of PTSD in recent trauma survivors: results of the International Consortium to Predict PTSD (ICPP). *World Psychiatry* **18**, 77–87.
- Sharma S, Powers A, Bradley B and Ressler KJ (2016) Gene  $\times$  environment determinants of stress- and anxiety-related disorders. *Annual Review of Psychology* **67**, 239–261.
- Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D and Bouter LM (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology* **7**, 10.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Journal of the American Medical Association* **283**, 2008–2012.
- Sullivan PF, Agrawal A, Bulik CM, Andreassen OA, Borglum AD, Breen G, Cichon S, Edenberg HJ, Faraone SV, Gelernter J, Mathews CA, Nievergelt CM, Smoller JW and O’Donovan MC (2018) Psychiatric genomics: an update and an agenda. *American Journal of Psychiatry* **175**, 15–27.
- Tarricone I, Stivanello E, Poggi F, Castorini V, Marseglia MV, Fantini MP and Berardi D (2012) Ethnic variation in the prevalence of depression and anxiety in primary care: a systematic review and meta-analysis. *Psychiatry Research* **195**, 91–106.
- Uher R and Zwickler A (2017) Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness. *World Psychiatry* **16**, 121–129.
- van Steensel FJA, Bögels SM and Perrin S (2011) Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. *Clinical Child and Family Psychology Review* **14**, 302–317.